De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Icade Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Nicolas Joly

Algemeen directeur

€728.0k

Totale compensatie

Percentage CEO-salaris	42.7%
Dienstverband CEO	1.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Nicolas Joly's beloning veranderd ten opzichte van Icade's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€953m
Mar 31 2024	n/a	n/a	-€1b
Dec 31 2023	€728k	€311k	-€1b

Compensatie versus markt: De totale vergoeding ($USD 805.81K ) Nicolas } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 1.40M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Nicolas te vergelijken met de prestaties van het bedrijf.

CEO

Nicolas Joly (41 yo)

1.5yrs

Tenure

€727,972

Compensatie

Mr. Nicolas Joly has been Chief Executive Officer of Icade since April 21, 2023. Mr. Joly served as Deputy Director-General at Mercialys and had been its Executive Vice-President since 2016. Mr. Joly joine...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nicolas Joly	Chief Executive Officer	1.5yrs	€727.97k	geen gegevens
Christelle De Robillard	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Sophie Duval	Head of Consolidation & Accounting	no data	geen gegevens	geen gegevens
Anne-Violette Faugeras	Director of Financing & Investor Relations	1.8yrs	geen gegevens	geen gegevens
Jérôme Lucchini	General Secretary and Head of Governance	9yrs	geen gegevens	geen gegevens
Emmanuelle Baboulin	Head of the Commercial Property Investment Division	9.1yrs	geen gegevens	geen gegevens
Xavier de La Sudrie	Head of Financial Control	no data	geen gegevens	geen gegevens
Johannah Mrejen	Head of Asset Management	no data	geen gegevens	geen gegevens
Guillaume Tessler	Head of International Development - Icade Santé	no data	geen gegevens	geen gegevens
Henri Chapouthier	Head of Sustainable Development	no data	geen gegevens	geen gegevens
Cathy Baglin	Head of Employee Affairs	no data	geen gegevens	geen gegevens
Benjamin Ficquet	Head of Property Management & Responsible Operations	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ICAD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bernard Spitz	Director	4yrs	€33.25k	0% € 0
Gonzague de Pirey	Independent Director	5.5yrs	€28.00k	0.00011% € 2.2k
Frederic Thomas	Chairman of the Board	8.4yrs	€240.00k	0.000040% € 799.6
Olivier Mareuse	Director	13.4yrs	geen gegevens	0% € 0
Marianne Louradour	Director	5yrs	geen gegevens	0% € 0
Antoine Saintoyant	Director	4yrs	geen gegevens	0% € 0
Sophie Quatrehomme	Director	6.6yrs	geen gegevens	0% € 0
Florence Peronnau	Vice Chairman of the Board & Lead Independent Director	8.4yrs	€101.25k	0.000010% € 199.9
Alexandre Thorel	Director	2.6yrs	geen gegevens	geen gegevens
Olivier Lecomte	Independent Director	less than a year	geen gegevens	0.000010% € 199.9
Emmanuel Chabas	Director	5.5yrs	geen gegevens	0% € 0
Laurence Giraudon	Director	4.7yrs	geen gegevens	0% € 0

5.3yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ICAD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Icade Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Icade, Annual General Meeting, Apr 19, 2024

Recent updates

Price target increased by 7.4% to €30.32

First half 2024 earnings released: €2.38 loss per share (vs €6.80 loss in 1H 2023)

Now 23% undervalued after recent price drop

Now 21% undervalued

Now 20% undervalued

Price target decreased by 7.8% to €29.59

Price target decreased by 8.3% to €32.09

Price target decreased by 7.9% to €32.82

Dividend of €2.42 announced

Now 21% undervalued after recent price drop

Upcoming dividend of €2.42 per share

Icade, Annual General Meeting, Apr 19, 2024

Consensus EPS estimates upgraded to €6.67 loss, revenue downgraded

Consensus EPS estimates fall by 69%

Consensus EPS estimates fall by 63%

Icade to Report Q1, 2024 Results on Apr 22, 2024

Icade to Report First Half, 2024 Results on Jul 22, 2024

Icade to Report Fiscal Year 2023 Results on Feb 19, 2024

Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)

Price target decreased by 7.3% to €41.55

Consensus EPS estimates fall by 160%

Now 20% undervalued after recent price drop

Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders.

Upcoming dividend of €2.17 per share at 12% yield

Consensus estimates of losses per share improve by 75%

Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS.

Consensus EPS estimates fall by 17%, revenue upgraded

Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD).

Consensus EPS estimates fall by 17%

Consensus estimates of losses per share improve by 16%

Consensus EPS estimates fall by 15%

An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million.

Icade SA (ENXTPA:ICAD) acquired Défense Parc complex in Nanterre Préfecture for €63 million.

Icade SA to Report Q1, 2023 Results on Apr 24, 2023

Icade SA to Report Fiscal Year 2022 Results on Feb 20, 2023

Consensus forecasts updated

Consensus forecasts updated

Elysées Pierre signed a bilateral preliminary agreement to acquire 16,000-Sq.m AXE 13 Office Building in Nanterre from Icade (ENXTPA:ICAD).

Investor sentiment deteriorated over the past week

Upcoming dividend of €2.10 per share

Funds managed by Primonial REIM acquired Gambetta building in paris from Icade (ENXTPA:ICAD) for approximately €220 million.

Funds managed by Primonial REIM acquired Gambetta building in paris from Icade (ENXTPA:ICAD) for approximately €220 million.

Residences Le Logement Des Fonctionnaires SA signed a bilateral preliminary agreement to acquire Residual Residential Portfolio from Icade (ENXTPA:ICAD) for €49.9 million.

Icade (ENXTPA:ICAD) acquired 50.1% interest in M&A Group.

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

An unknown buyer completed the acquisition of Office building in Boulogne-Billancourt from Icade SA (ENXTPA:ICAD).

Consensus EPS estimates increase to €1.91

Consensus EPS estimates increase to €1.10

First half 2021 earnings released: EPS €2.52 (vs €0.07 in 1H 2020)

Consensus forecasts updated

Revenue beats expectations, earnings disappoint

A Look At Icade's (EPA:ICAD) Share Price Returns

New 90-day low: €55.50

Analysts update estimates

How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?

A pan-European fund dedicated to a German institutional investor managed by Aberdeen Standard Investments Limited acquired Two residential buildings in Rueil-Malmaison from Icade SA (ENXTPA:ICAD) for €14.6 million.

Icade SA (ENXTPA:ICAD) acquired Ad Vitam

Icade SA to Report Q1, 2021 Results on Apr 23, 2021

Icade SA (ENXTPA:ICAD) agreed to acquire Four Nursing Homes in France from Korian (ENXTPA:KORI) for €33.5 million.

What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?

New 90-day high: €68.20

Market bids up stock over the past week

New 90-day low: €42.96

New 90-day low: €48.00

Analysts lower EPS estimates to €1.11

New 90-day low - €54.25

OPPCI owned by South Korean Investors completed the acquisition of 49% stake in Eqho Tower from Icade (ENXTPA:ICAD).

Icade (ENXTPA:ICAD) completed the acquisition of Pointe Métro 1 in Gennevilliers from Fonciere NW 2 Sppicav managed by NORMANDIE REIM.

New 90-day low - €55.45

Icade SA (ENXTPA : ICAD) agreed to acquire Portfolio of 9 Healthcare Facilities in Germany & France from Orpea SA (ENXTPA : ORP) for €145 million.

Analyse CEO-vergoeding